ARDX
ARDELYX, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.29
+8.58%Year over year
Reported trailing growth
- Revenue
- +17.6%
- EBITDA
- -9.4%
- EBIT
- +4.9%
- EPS
- +4.0%
- Free cash flow
- +71.2%
- Operating cash flow
- +71.1%
Forward estimates
Based on analyst estimates
- Revenue
- +16.9%
- EBITDA
- +276.0%
- EPS
- +121.8%
Three-year CAGR
- Revenue
- +98.4%
- EBITDA
- -74.6%
- EBIT
- -46.6%
- Net income
- -57.4%
- EPS
- -52.9%
- Free cash flow
- +4.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026